Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living with HIV: A Phase 1, Dose-Escalation Trial

Investigators administered a recombinant bicistronic adeno-associated virus (AAV8) vector coding for both the light and heavy chains of the potent broadly neutralizing HIV-1 antibody VRC07 to eight adults living with HIV.